Max Healthcare Q2 PAT rises 10% to ₹448 cr on higher bed occupancy
Max Healthcare moved higher in a quarterly results development for Q2 FY27.
· BS Companies
Max Healthcare's Q2 FY27 network profit rose 10.34% to ₹448 crore, while gross revenue grew 20% to ₹3,219 crore, driven by higher bed occupancy and international patient demand.
Key facts
- Period
- Q2 FY27
The analysis
Max Healthcare reported ₹448 cr, ₹448 crore and ₹3,219 crore for Q2 FY27, with movement of 10%, 20% and 10.34% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +1.0% on the day at ₹860.00, and has returned -23.5% over three months. It sits 27% below its 52-week high, which means a good deal of bad news was already in the price. The pharma & healthcare sector has moved -0.9% over the same period, so Max Healthcare is running 22.6 points behind its peers.
For Max Healthcare, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Max Healthcare (MAXHEALTH), in Pharma & Healthcare.
- Over three months: Max Healthcare -23.5% against Pharma & Healthcare -0.9% (22.6 points behind).
- At least 25% below the 52-week high: Max Healthcare (27%).
- Trading well above normal today: Max Healthcare at 2.0 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Max HealthcareMAXHEALTH · Pharma & Healthcare | ₹860.00 | +1.0% | -7.5% | -23.5% | -27.2% | 2.0× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Max Healthcare
Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report